Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has signed a distributor agreement with the Research Institute for Liver Diseases (RILD) in Shanghai, People’s Republic of China. Mr. John DiBella, vice president for marketing and sales for Simulations Plus, said, “We’re very pleased to be working with the RILD to offer in silico consulting services using our various software programs in support of RILD’s in vitro experimental systems to its customers in China. Dr. Zhuohan Hu, President and CEO of RILD, is highly respected within the pharmaceutical industry in China, and we look forward to leveraging his connections with researchers at regulatory agencies and local companies to continue penetrating this growing market. We expect this new dealership to help promote our consulting services in the areas of drug absorption, toxicity, metabolism, and drug-drug interactions.” About RILD The Research Institute for Liver Diseases (Shanghai) Co. (RILD) is the first contract research organization in China dedicating itself to providing in vitro ADMET services and products to support drug development. Founded in 2002, RILD’s in vitro ADMET services, including metabolism and transporter substrate, inhibitor, and induction studies, are sponsored and certified by all major Chinese government agencies, and they count many international and local pharmaceutical companies and universities as clients. About Simulations Plus, Inc. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com. Follow Us on Twitter Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.